Cite

HARVARD Citation

    Zhao, X. et al. (n.d.). 1232PModel-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types. Annals of oncology. p. . [Online]. 
  
Back to record